A phase I trial of BIA 102474

Trial Profile

A phase I trial of BIA 102474

Discontinued
Phase of Trial: Phase I

Latest Information Update: 10 Mar 2016

At a glance

  • Drugs BIA 102474 (Primary)
  • Indications Pain
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Mar 2016 New trial record
    • 19 Jan 2016 According to BIAL media release, as of June 2015, the French Regulatory Authorities and by the French Ethics Committee, in accordance with Good Clinical Practices, with the Declaration of Helsinki and the inherent clinical trials related legislation approved for this trial but BIAL was informed about the occurrence of an adverse effect in a volunteer on the 11th January, BIAL immediately decided to discontinue the medication to all the participants in the trial.
    • 19 Jan 2016 Status changed from recruiting to discontinued, as reported by BIAL media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top